Literature DB >> 8670594

Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus.

P E Spronk1, H Bootsma, G Horst, M G Huitema, P C Limburg, J W Tervaert, C G Kallenberg.   

Abstract

Antineutrophil cytoplasmic antibodies (ANCA) with specificity for proteinase-3 (PR3) are associated with Wegener's granulomatosis, and ANCA directed to myeloperoxidase (MPO) with other idiopathic vasculitides. Inflammation of small-sized blood vessels is a hallmark of systemic lupus erythematosus (SLE). We evaluated the prevalence of ANCA in SLE, their antigenic specificities, and their possible relation to clinical disease patterns and activity. Plasma samples from 84 patients with SLE were tested for ANCA during remission. Plasma samples from the 25 patients who relapsed during a follow-up of 32 months were serially analysed for ANCA in a 6 month period preceding and including the relapse. The presence of ANCA was assessed by indirect immunofluorescence (IIF) and ELISA for antibodies to PR3, MPO, lactoferrin (LF), elastase (HLE) and cathepsin-G (CG). We related the presence of ANCA to disease patterns, activity and duration. ANCA by IIF were difficult to interpret dut to the presence of antinuclear antibodies (ANA). By ELISA, we found no anti-PR3 or anti-HLE. Anti-MPO (n = 7), anti-LF (n = 13) and anti-CG (n = 10) were detected, generally in low titres. The presence of ANCA of defined specificity was not associated with specific clinical subsets. The prevalence of ANCA was higher in patients who developed relapses than in those who did not (P < 0.01). However, levels of ANCA did not fluctuate in the period preceding the relapse. ANCA of various specificities occur in SLE. Their presence is not associated with specific clinical disease entities. The higher frequency of ANCA in relapsing patients compared to those who do not relapse may suggest that ANCA are involved in disease expression. Their diagnostic significance is limited.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670594     DOI: 10.1093/rheumatology/35.7.625

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  21 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 2.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe.

Authors:  N Sangala; R W Lee; C Horsfield; D J A Goldsmith
Journal:  Int Urol Nephrol       Date:  2009-08-15       Impact factor: 2.370

4.  pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.

Authors:  L K Gordon; M Eggena; G N Holland; J M Weisz; J Braun
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

5.  Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates.

Authors:  Domenico Caccavo; Amelia Rigon; Antonio Picardi; Sara Galluzzo; Marta Vadacca; Giovanni Maria Ferri; Antonio Amoroso; Antonella Afeltra
Journal:  Clin Rheumatol       Date:  2004-12-09       Impact factor: 2.980

6.  Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.

Authors:  Abdul Hakkim; Barbara G Fürnrohr; Kerstin Amann; Britta Laube; Ulrike Abu Abed; Volker Brinkmann; Martin Herrmann; Reinhard E Voll; Arturo Zychlinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

7.  Demographic, autoimmune, and clinical profiles of patients with systemic lupus erythematosus in Oman.

Authors:  M H Al-Maini; E M El-Ageb; S S Al-Wahaibi; Y Al-Farsi; E R Richens
Journal:  Rheumatol Int       Date:  2003-04-02       Impact factor: 2.631

8.  Anti-CD3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus (SLE).

Authors:  M Bijl; G Horst; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

Review 9.  Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome?

Authors:  B Hervier; M Hamidou; J Haroche; C Durant; A Mathian; Z Amoura
Journal:  Rheumatol Int       Date:  2011-07-30       Impact factor: 2.631

10.  Antineutrophil cytoplasmic antibodies in childhood systemic lupus erythematosus.

Authors:  A Bakkaloglu; R Topaloglu; U Saatçi; S Ozdemir; S Ozen; Y Başsoy; N Beşbaş
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.